Latanoprost/timolol

Latanoprost/timolol
Combination of
Latanoprost	Prostaglandin
Timolol	Beta blocker
Clinical data
Trade names	Xalacom
Routes of; administration	Eye drops
ATC code	S01ED51 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only);
Identifiers
PubChem CID	56841581;
KEGG	D07505;
CompTox Dashboard (EPA)	DTXSID401005716 ;

Latanoprost/timolol, sold under the brand name Xalacom, is a combination drug used for the treatment of glaucoma, consisting of latanoprost (increase uveoscleral outflow of aqueous humor^[3]) and timolol (a beta blocker decreasing the production of aqueous fluid).

Society and culture

In some countries, Xalacom is marketed by Viatris after Upjohn was spun off from Pfizer.^[4]^[5]

^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
^ "Summary of Product Characteristics (SmPC)". (emc). 13 June 2022. Retrieved 31 March 2024.
^ Patel SS, Spencer CM (1996). "Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension". Drugs Aging. 9 (5): 363–378. doi:10.2165/00002512-199609050-00007. PMID 8922563. S2CID 25169085.
^ "Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan". Pfizer. 16 November 2020. Retrieved 17 June 2024 – via Business Wire.
^ "Brands". Viatris. 16 November 2020. Retrieved 17 June 2024.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.